Arcadia Biosciences, Inc. (RKDA) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated March 26, 2026, announces the financial results for Arcadia Biosciences, Inc. for the fourth quarter and the full year ended December 31, 2025. The company is incorporated in Delaware and trades on The Nasdaq Stock Market LLC under the symbol RKDA.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained in the press release (Exhibit 99.1) and financial information tables (Exhibit 99.2) referenced in the report but not included in the provided text.
Material Changes
The filing does not explicitly detail material changes versus the prior comparable period within the body text. Investors must refer to the attached exhibits for comparative financial data and analysis of year-over-year performance.
Guidance, Outlook, and Risks
Management commentary, business highlights, and any forward-looking guidance are located in the press release furnished as Exhibit 99.1. The filing includes standard disclaimers stating that the information in Item 2.02 and the exhibits shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and shall not be incorporated by reference into other SEC filings.
Investor Verification Checklist
- Review Exhibit 99.1 for specific Q4 and full-year 2025 revenue and net income figures.
- Examine Exhibit 99.2 for detailed cash flow, liquidity, and debt position data.
- Verify any updated financial guidance or strategic outlook provided in the press release.
- Confirm the status of the company's cash runway given the lack of specific liquidity numbers in the 8-K summary text.